Jiang Fan, Fan Junjie, Liang Hua, Duan XiaoYi, He Dalin, Wu Kaijie
Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Urology, Baoji Central Hospital, Baoji, China.
Front Med (Lausanne). 2022 Apr 6;9:842093. doi: 10.3389/fmed.2022.842093. eCollection 2022.
Prostate lymphoma (PL) is rarely observed and may be concurrently presented with prostate adenocarcinoma. Moreover, the appearance of PL on conventional imaging is similar with prostate adenocarcinoma. Thus, most of PL is diagnosed through prostate biopsy, or accidentally found in the specimens of surgery. Prostate-specific membrane antigen (PSMA) PET/CT has improved the management of prostate adenocarcinoma. While, the question regarding whether it benefits the discovery of the characteristics of PL is unknown. A 32-year-old man presented with worsening dysuria for 1 month, and the prostate-specific antigen (PSA) concentration was normal. While the pelvic MRI showed a mass in the prostate and multiple enlarged lymph nodes in the bilateral inguinal area. Then, the diagnosis of prostate adenocarcinoma was considered, but the serum PSA was normal and he was younger than most patients. So, 18F-PSMA PET/CT was then performed to further reveal the characteristics of the lesion and guide biopsy. However, there was no abnormal PSMA uptake in the lesion of the prostate and lymph nodes of the pelvic cavity and bilateral inguinal area. These lesions presented with increased glucose metabolism on fluorodeoxyglucose (FDG) PET/CT, and the prostate biopsy was then performed. PL was confirmed based on the results of the histopathologic examination, and the patient subsequently received systemic chemotherapy plus radiotherapy. Fortunately, the symptoms and the lesions completely disappeared after radiotherapy. The clinical symptoms of PL are atypical, and PL and adenocarcinoma may be concurrently presented. Moreover, distinguishing PL from prostate adenocarcinoma based on the appearance of conventional imaging is difficult. As opposed to prostate adenocarcinoma, a high FDG-avidity and low PSMA uptake by lymphoma either in the prostate or metastases are seen. So, PSMA PET/CT combined with FDG PET/CT can non-invasively identify the characteristics and origin of PL.
前列腺淋巴瘤(PL)较为罕见,可能与前列腺腺癌同时出现。此外,PL在传统影像学上的表现与前列腺腺癌相似。因此,大多数PL是通过前列腺活检诊断出来的,或者是在手术标本中偶然发现的。前列腺特异性膜抗原(PSMA)PET/CT改善了前列腺腺癌的治疗。然而,关于它是否有助于发现PL的特征尚不清楚。一名32岁男性出现排尿困难加重1个月,前列腺特异性抗原(PSA)浓度正常。盆腔MRI显示前列腺有肿块,双侧腹股沟区有多个肿大淋巴结。当时考虑诊断为前列腺腺癌,但血清PSA正常且患者比大多数患者年轻。于是,进行了18F-PSMA PET/CT检查以进一步揭示病变特征并指导活检。然而,前列腺病变以及盆腔和双侧腹股沟区淋巴结均未出现PSMA摄取异常。这些病变在氟脱氧葡萄糖(FDG)PET/CT上表现为葡萄糖代谢增加,随后进行了前列腺活检。根据组织病理学检查结果确诊为PL,患者随后接受了全身化疗加放疗。幸运的是,放疗后症状和病变完全消失。PL的临床症状不典型,且PL可能与腺癌同时出现。此外,基于传统影像学表现区分PL和前列腺腺癌很困难。与前列腺腺癌不同,淋巴瘤在前列腺或转移灶中表现为高FDG摄取和低PSMA摄取。因此,PSMA PET/CT与FDG PET/CT联合应用可以无创地识别PL的特征和来源。